Individual Treatment of Ustekinumab in Perianal Fistulizing Crohn's Disease

ConditionCrohn Disease
Trial statusNot yet recruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18-65
SponsorSecond Affiliated Hospital of Wenzhou Medical University

About this trial

This study intends to further explore the actual efficacy of ustekinumab in the individualized treatment of anal fistula Crohn's disease.

Eligibility criteria

Qualifiers

Clinical diagnosis of Perianal Fistulizing Crohn's Disease

Receive ustekinumab therapy

Disqualifiers

Ustekinumab combined with hormones, immunosuppressants, other biologics or small molecule drugs

Combined with other autoimmune diseases, such as systemic lupus erythematosus, rheumatoid arthritis, Graves disease, etc.

Combined with serious infectious diseases, such as active tuberculosis, EBV infection, cytomegalovirus infection, etc.

Combined with malignant tumor

Trial design

Treatments tested in this trial

  • Not listed

Trial groups

No trial groups listed